>Brookings Oregon News, Sports, & Weather | The Curry Coastal Pilot

News Classifieds Web
web powered by Web Search Powered by Google

News arrow News arrow Business arrow Brookings’ newest coffee shop comes with an island attitude

Brookings’ newest coffee shop comes with an island attitude Print E-mail
Written by The Curry Coastal Pilot   
March 24, 2010 10:06 am

Sherry Martinez brings her island dreams to Brookings with the Hawaiian-themed Jitter Hut, located in the Subway sandwich shop.
Sherry Martinez brings her island dreams to Brookings with the Hawaiian-themed Jitter Hut, located in the Subway sandwich shop.
A new coffee shop is in town, serving Hawaiian Kona coffee, fruit smoothies and a side of island attitude.

Three weeks ago Sherry Martinez brought her vision of Jitter Hut, an island-themed shop, to match her Hawaiian coffee.

Jitter Hut, located inside the Subway sandwich shop at 1006 Chetco Ave., features 100 percent Kona Coffee, in both liquid and bean form, and 100 percent fruit smoothies.

The island spirit comes through with “long board,” “short board” and “boogie board” (large-, medium- and small- sized drinks,) and beverages such as “Beach Bum Rush,” “Lava Bomb,” and “Rip Curl.”

The shop will also offer chocolate covered macadamia nuts, chocolate covered kona coffee beans and other treats, such as a macadamia nut hand-dipped in chocolate 200 times.

Martinez made a go of it in Florida, but it didn’t work out.

“As an Oregonian, I wanted to come home.” she said.

After looking into the options on the Oregon Coast, Martinez heard about the Subway location.

With her palm-tree carved tiki men, parrots and bamboo paneling, Martinez moved in.

The store will host grand-opening activities later this spring, including a “name the tiki” contest, with free drinks for three winners, Martinez said.

Jitter Hut is open 6 a.m. to 5 p.m. daily and offers drive-through service, and both indoor and outdoor seating.

Jitter Hut can be reached at 541-412-2777.

 

Business News by Yahoo Finance

  • Economy seen regaining muscle in second quarter
    U.S. economic growth likely regained steam in the second quarter as activity picked up broadly, which would bolster expectations for a stronger performance in the last six months of the year. Gross domestic product likely grew at a 3.0 percent annual rate after shrinking at a 2.9 percent pace in the first quarter, according to a Reuters survey of economists. "I don't think the contraction we saw in the first quarter is reflective of what's truly going on in the economy," said Gus Faucher, senior economist at PNC Financial Services Group in Pittsburgh. Earlier in the second quarter, growth estimates were as high as 4 percent, but they were cut as trade, consumer spending and business investment rebounded from the winter slump by less than expected.
  • Asian shares hit six and a half year high, dollar steady before Fed
    Asian shares touched a six-and-half-year peak on Wednesday and the dollar was steady, with investors waiting for second quarter U.S. growth data as well as a U.S. Federal Reserve meeting that some believe might yield a more hawkish policy outlook. The Fed will not be updating its economic forecasts and Chair Janet Yellen will not hold a news conference following the two-day policy meeting, leaving investors' focus squarely on a statement scheduled to be released at 2 p.m. (18:00 GMT).
  • AstraZeneca buys Almirall lung drugs for up to $2.1 billion
    AstraZeneca (AZN.L) took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's (ALM.MC) lung drugs. The British drugmaker, which resisted a $118 billion takeover attempt by Pfizer (PFE.N) in May, said it would pay an initial $875 million and up to $1.22 billion more if the drugs meet development and sales targets. The tie-up boosts a key therapeutic area for AstraZeneca, whose Chief Executive Pascal Soriot is determined to show his company has a strong independent future. Soriot also struck a clinical trial collaboration with Japan's Kyowa Hakko Kirin (4151.T) for a study that will evaluate a combination of the two companies' drugs in cancer - another important field for AstraZeneca.

Follow Curry Coastal Pilot headlines on Follow Curry Coastal Pilot headlines on Twitter

© Copyright 2001 - 2014 Western Communications, Inc. All rights reserved. By Using this site you agree to our Terms of Use